Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health MRD Test Garners Coverage From Blue Cross, Blue Shield of Louisiana

NEW YORK – Guardant Health said Thursday that Blue Cross and Blue Shield of Louisiana will now cover the use of its Guardant Reveal molecular residual disease test for serial testing of colorectal cancer patients after surgery.

The company's test detects circulating tumor DNA (ctDNA) in patient blood samples and is intended to aid oncologists in detecting cancer recurrences after initial, hopefully curative treatment.

The BCBS policy, effective July 10, is specific to patients with stage II or III colorectal cancer and provides for a testing frequency aligned with monitoring guidelines established by the National Comprehensive Cancer Network. This includes an initial ctDNA test four to six weeks after surgery or two to four weeks after completion of systemic therapy, followed by serial monitoring every three to six months for the first two years and every six to 12 months for the following three years.

In morning trade on the Nasdaq, Guardant Health's stock was down a fraction of a percent at $37.63.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.